Highlights

  • EBR Systems completed 41 commercial WiSE implants during Q1 2026, more than doubling implant Volume from the prior quarter.
  • Quarterly Revenue reached US$2.4 million (A$3.4 million), compared with US$935,000 in Q4 2025.
  • Total commercial implants across the pilot phase and Limited Market Release increased to 71.
  • The company signed 16 additional purchase agreements and trained 22 more physicians during the quarter.
  • Net operating cash outflows totalled US$20.3 million during Q1 2026 as the company continued investing in commercialisation infrastructure and Manufacturing capability.

EBR Systems (ASX:EBR) released its Q1 2026 quarterly update outlining continued commercial expansion for its WiSE CRT System in the United States, alongside growing implant activity, rising revenue and additional physician Training. The update also highlighted ongoing cash outflows and continued Investment in commercial infrastructure as the company scales operations following its U.S. market launch.

During the afternoon session on 12 May 2026, EBR Systems shares traded 10.00% lower at AUD 0.54. The stock remains down 49.53% over the past year. While the Quarterly Report included several operational milestones tied to commercial rollout and regulatory progress, investors also appeared to focus on elevated operating cash outflows, Margin pressures and ongoing commercialisation expenses.

EBR Systems is a medical device company focused on cardiac rhythm management technologies. The company developed the WiSE CRT System, described as the world’s only wireless cardiac pacing system for heart failure patients requiring cardiac resynchronisation therapy. The technology is designed for patients who are unable to benefit from conventional CRT systems.

Commercial Implant Activity Accelerates

A key feature of the quarterly update was continued growth in commercial implantation activity across EBR’s Limited Market Release program in the United States.

The company completed 41 commercial WiSE implants during Q1 2026, more than doubling implant volumes compared with Q4 2025. Total commercial implants completed since the commencement of the pilot launch and Limited Market Release phase now stand at 71.

Revenue for the quarter reached US$2.362 million, compared with US$935,000 in the previous quarter.

The majority of quarterly revenue came from sales of the WiSE CRT System, which generated US$2.32 million during Q1 2026. Additional contributions came from surgical tool kits and battery replacement revenue.

Management stated that increasing utilisation across participating centres reflected continued progress in site activation, physician education, purchase agreement execution and case scheduling activities.

EBR also noted that Medicare reimbursement pathways are now in place for both inpatient and outpatient settings, which management believes provides additional support for future commercial adoption.

Physician Training and Purchase Agreements Expand

The company continued broadening its commercial infrastructure during the quarter.

A total of 22 additional physicians were trained to implant the WiSE system during Q1 2026, lifting the total trained physician base to 55.

According to the company, this represented an increase of nearly 70% in trained physicians compared with prior periods.

EBR also signed 16 new purchase agreements with target hospitals and treatment centres during the quarter, adding to the 21 agreements secured previously.

Management indicated that the company remains focused on a controlled commercial rollout strategy designed to prioritise procedural consistency, physician experience, patient outcomes and hospital workflow development.

Hospital education efforts relating to reimbursement pathways under NTAP and TPT programs also continued during the quarter.

EBR’s President and Chief Executive Officer John McCutcheon stated that the company remains focused on disciplined execution while building the infrastructure needed for broader commercial expansion over time.

TGA Priority Review Supports Australian Pathway

Subsequent to the end of the March quarter, EBR announced that the Therapeutic Goods Administration had granted Priority Review Determination for the WiSE CRT System.

The designation provides access to an accelerated regulatory review pathway toward inclusion on the Australian Register of Therapeutic Goods.

Management stated that the company intends to submit its ARTG application in the near term.

The milestone potentially supports earlier access to the WiSE system for Australian heart failure patients who have limited cardiac resynchronisation therapy Options available.

The TGA development follows earlier FDA approval in the United States and forms part of the company’s broader international commercialisation strategy.

Clinical Evidence Programs Continue

In addition to commercial rollout activities, EBR continued advancing its clinical evidence programs during the quarter.

The company maintained enrolment activity in both the WiSE-UP post-approval study and the TLC-AU feasibility study.

Management indicated that these studies are intended to further expand the body of clinical evidence supporting the WiSE system and its application in heart failure treatment.

EBR has continued positioning clinical evidence generation as an important component of physician adoption and long-term commercial strategy.

Operating Cash Outflows Remain Elevated

While the quarter demonstrated commercial growth, the update also highlighted continued investment requirements associated with scaling operations.

Net operating cash outflows during Q1 2026 totalled US$20.3 million, compared with US$15 million in Q4 2025.

The company stated that the increase partly reflected annual Bonus payments and payroll taxes totalling approximately US$2.3 million, which occur once per year.

Additional expenses included roughly US$1.3 million associated with WiSE demonstration and testing units used for commercialisation and research purposes.

EBR also invested US$2.6 million in leasehold improvements related to its new Facility during the quarter. Management noted that reimbursement from the landlord is expected during Q2 2026.

Staff costs increased to US$10.9 million during the quarter, while Advertising and Marketing expenses rose to US$2.7 million as the company continued supporting commercial expansion efforts.

Research and Development expenditure totalled US$2.6 million during Q1 2026.

Gross Margin Remains Under Pressure

The quarterly report also provided additional detail on product margin performance.

EBR reported a gross margin of 7.8% during Q1 2026.

Management explained that the margin outcome was favourably impacted by the use of inventory that had previously been expensed during clinical trial activity.

Excluding the benefit of previously expensed inventory, the company stated that gross margin would have been negative 25.4%.

The company indicated that margins are expected to continue reflecting temporary favourable inventory impacts in the near term before improving organically over time.

This aspect of the update may have contributed to a more cautious market reaction despite higher revenue and implant growth.

Cash Position and Liquidity

As of 31 March 2026, EBR held total cash, cash equivalents, restricted cash and marketable securities of approximately US$33.5 million, equivalent to around A$48.8 million.

This included:

  • US$6.6 million in cash and cash equivalents.
  • US$2.6 million in restricted cash.
  • US$24.3 million in marketable securities.

The company stated that its investments are held primarily in fixed-income instruments with relatively short average maturities and minimum investment-grade Credit ratings.

Corporate Changes During the Quarter

EBR also completed a 1-for-10 Reverse Stock Split following Shareholder approval received in March 2026.

The company clarified that its CHESS Depositary Interests were not consolidated directly. Instead, the CDI-to-common-share conversion ratio changed from 1:1 to 10:1.

Management stated that the adjustment did not alter the number of CDIs held by investors, aside from minor rounding differences, and did not impact ownership proportions.

What This Means for Investors?

EBR Systems’ Q1 2026 update presented a combination of growing commercial activity and continued operating investment as the company expands the rollout of its WiSE CRT System.

On the positive side, implant volumes more than doubled from the prior quarter, revenue increased materially, physician training expanded and the company secured additional purchase agreements and regulatory progress in Australia.

However, the report also highlighted elevated operating cash outflows, ongoing margin pressure and increasing commercialisation costs associated with scaling infrastructure and supporting broader adoption.

The market reaction suggests investors may currently be balancing the company’s commercial growth trajectory against the financial demands of expanding a medical technology platform during the early stages of commercial rollout.

Future investor attention is likely to remain focused on implant growth, revenue progression, reimbursement adoption, margin improvement and regulatory developments across additional markets.